CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (3,452,779)	$ (4,883,827)
Adjustments to reconcile net loss to net cash used by operating activities:
Non-cash compensation	477,732	261,747
Depreciation and amortization	181,368	138,175
Amortization of debt costs	35,868	23,754
Bad debt	7,862	14,193
Stock-based compensation	729,429	227,658
Foreign currency transaction loss	668,488	393,455
Changes in operating assets and liabilities:
Grants and accounts receivable	(1,023,329)	611,668
Inventories	134,270	(395,683)
Prepaid expenses and other current assets	87,107	435,423
Accounts payable and accrued expenses	(1,055,356)	(1,064,124)
Net cash used by operating activities	(3,209,340)	(4,237,561)
Cash flows from investing activities:
Purchases of property and equipment	(235,551)	(292,458)
Payments for patent costs	(273,011)	(181,769)
Net cash used by investing activities	(508,562)	(474,227)
Cash flows from financing activities:
Equity contributions - net of fees incurred	17,743,226	0
Proceeds from exercise of stock options	138,430	236,070
Proceeds from exercise of warrants	0	1,768,491
Net cash provided by financing activities	17,881,656	2,004,561
Effect of exchange rates on cash	(7,151)	(14,236)
Net change in cash and cash equivalents	14,156,603	(2,721,463)
Cash and cash equivalents - beginning of period	12,232,418	22,368,837
Cash and cash equivalents - end of period	26,389,021	19,647,374
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	318,879	227,681
Supplemental disclosure of non-cash financing activities
Settlement of accrued bonuses with restricted stock units	328,939	425,639
Equity contribution proceeds in transit	$ 1,798,395	$ 0